Hims & Hers' introduction of a $49 compounded version of Wegovy has triggered a sharp decline in Novo Nordisk's stock, underscoring growing competition in the weight-loss drug market. The lower-cost alternative challenges the high price of the branded oral formulation.
- Hims & Hers launched a compounded semaglutide pill priced at $49 per month
- This is $100 less than the $149 starting cost of branded oral Wegovy
- Novo Nordisk’s shares declined 5.3% in after-hours trading
- Compounded formulations are not FDA-approved but are legally available via compounding pharmacies
- The move intensifies competition in the GLP-1 drug market and may influence insurance coverage decisions
- Patients and providers are increasingly turning to lower-cost alternatives amid high drug prices
Hims & Hers announced the launch of a compounded version of semaglutide, marketed as a generic alternative to Novo Nordisk’s Wegovy, priced at $49 per month. This marks a significant reduction from the $149 starting cost of the branded oral Wegovy formulation. The new offering is delivered through a compounding pharmacy model, allowing for faster patient access and lower overhead costs. The move signals a shift in the weight-loss pharmaceutical landscape, where direct-to-consumer telehealth platforms are increasingly undercutting established drugmakers. Novo Nordisk, the developer and exclusive marketer of Wegovy, saw its shares drop by 5.3% in after-hours trading following the announcement. The decline reflects investor concerns over pricing pressure and erosion of market share in a rapidly evolving space. The $49 price point is particularly disruptive, as it aligns with the cost of generic semaglutide injectables but offers a more accessible oral form. Analysts note that compounded formulations, while not FDA-approved as a branded product, are legally available and often used in clinical practice when patients seek alternatives to expensive branded drugs. The development is expected to impact not only Novo Nordisk’s revenue forecasts but also broader insurance reimbursement dynamics. As more providers adopt lower-cost compounding solutions, payers may reconsider prior authorization requirements and formulary placements for branded GLP-1 agonists.